Combining preoperative stereotactic ablative radiotherapy (SBRT) with anti-PD-1 immunotherapy will significantly increase the pathological complete response rate in patients with stage 1 NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.